Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200229 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9HDAC7HDAC8 | |
| SCHEMBL13887116 | 1.00 | DPP4 (0.44) | DPP4DPP8DPP9HDAC7HDAC8 | |
| SCHEMBL9650376 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9CA1CA2 | |
| SCHEMBL8122592 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL15731847 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL8122591 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL9650387 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9CA1CA2 | |
| SCHEMBL6686776 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL9969913 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL3661089 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009504-B1 | MICROORGANISM PRODUCING L-ISOLEUCINE AND METHOD FOR PREPARING L-ISOLEUCINE USING THE SAME | CJ CHEILJEDANG CORP (KR) | 2020-12-02 | — | — | EP | claimed |
| CN-105378059-B | Produce l-Isoleucine microorganism and the method using the micro-organisms l-Isoleucine | CJ第制糖株式会社 | 2018-12-28 | — | — | CN | claimed |
| CN-105378059-A | Microorganism producing l-isoleucine and method for preparing L-isoleucine using same | CJ CHEILJEDANG CORP | 2016-03-02 | — | — | CN | claimed |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | NAUREX, INC. (US) | 2014-02-13 | — | — | US | claimed |
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | KHAN AMIN (US) | 2012-01-05 | — | — | US | claimed |
| WO-2010065709-A2 | HYDROXAMIC ACID DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | KHAN AMIN (US) | 2010-06-10 | — | — | WO | claimed |
| CN-119012914-A | Method for controlling parasitic plants | 味之素株式会社 | 2024-11-22 | — | — | CN | disclosed |
| CN-116121135-B | Corynebacterium glutamicum mutant strain and application thereof in L-isoleucine fermentation | 大连医诺生物股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-115052976-B | Novel acetohydroxyacid synthase variants and microorganisms comprising same | CJ第一制糖株式会社 | 2023-12-19 | — | — | CN | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| CN-116121135-A | Corynebacterium glutamicum mutant strain and application thereof in L-isoleucine fermentation | 大连医诺生物股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-101243177-A | Microorganism producing L-amino acid and method for producing L-amino acid | AJINOMOTO KK (JP) | 2008-08-13 | — | — | CN | disclosed |
| CN-101090964-A | Use of phosphoketolase for producing useful metabolites | AJINOMOTO KK (JP) | 2007-12-19 | — | — | CN | disclosed |
| CN-1954065-A | Method for producing L-amino acid by fermentation | AJINOMOTO KK (JP) | 2007-04-25 | — | — | CN | disclosed |
| CN-1297665-C | Nucleotide sequence of threonine operon irrepressible by isoleucine and method for producing L-threonine using transformed host cell containing the same | CJ CORP (KR) | 2007-01-31 | — | — | CN | disclosed |
| CN-1813065-A | Feedback resistant acetohydroxy acid synthethase mutants | DEGUSSA (DE) | 2006-08-02 | — | — | CN | disclosed |
| CN-1236066-C | Method for producing L-amino acid by fermentation method | KYOWA HAKKO KOGYO KK (JP) | 2006-01-11 | — | — | CN | disclosed |
| CN-1653180-A | Nucleotide sequence of threonine operon not inhibited by isoleucine and method for producing L-threonine using transformed host cell containing the same | CJ CORP (KR) | 2005-08-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | GLS, HGFAC, AADAC | DPP4 722/4885DPP8 697/4885DPP9 284/4885 |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | GLS, HGFAC, AADAC | DPP4 722/4885DPP8 697/4885DPP9 284/4885 |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | DPP4 4237/4885DPP8 3963/4885DPP9 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.